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Background: Aberrant expression of claudin proteins has been reported in a variety of cancers. Previous studies
have demonstrated that overexpression of claudin may promote tumorigenesis and metastasis through increased
invasion and survival of tumor cells. However, the prognostic significance of claudin-4 in gastric cancer remains
unclear.
Methods: Immunohistochemistry was used to analyze the expression of claudin-4 in 329 clinical gastric cancer
specimens and 44 normal stomach samples, 21 intestinal metaplasia samples, and 21 adjacent precursor lesions
dysplasia samples. Statistical analysis methods were used to evaluate the relationship between claudin-4 expression
and various clinicopathological parameters. Univariate and multivariate analyses were performed, respectively, to
detect the independent predictors of survival.
Results: Claudin-4 expression was present in only 7(15.9%) normal gastric samples, but expression of claudin-4 in the
intestinal metaplasia lesions and dysplasia lesions was 90.5% and 95.2%, respectively. The expression of claudin-4 was
significantly associated with histological differentiation (P < 0.001) and tumor growth patterns (P < 0.001) but not
associated with patient survival. However, intermediate type staining of claudin-4 exhibited a trend of correlation with
patients’ survival (P = 0.023). The five-year survival rate with low expression of claudin-4 in intermediate type (76.4%)
was similar to expanding type (64.5%), while the high expression group (46.6%) was closer to infiltrative type (50.7%).
Conclusions: The findings in this study demonstrate claudin-4 aberrant expression in gastric cancer and precursor
lesions. The expression of claudin-4 could serve as a basis for identifying gastric cancer of the intermediate type.
Keywords: Gastric carcinoma, Claudin-4, Tight junctionsBackground
Gastric cancer is one of the most common malignancies,
and approximately 738,000 deaths occurred due to gas-
tric cancer in 2008 worldwide. Over 70% of new cases
and deaths occur in developing countries, particularly in
Eastern Asia [1]. Gastric cancer is generally understood
to develop as a multistep progression from chronic gas-
tritis, atrophic gastritis, intestinal metaplasia, dysplasia,
and finally cancer [2]. During this process, loss of cell
polarity and disruption of cell-cell junctions is frequently* Correspondence: josieon826@yahoo.com.cn
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reproduction in any medium, provided the orobserved, and this plays an important role in cancer
progression.
Tight junctions (TJs) are critical for maintaining normal
structure and physiological function of the epithelium and
endothelium [3,4]. TJs not only serve as a physical barrier
to prevent solutes and water from passing freely through
the paracellular space between epithelial and endothelial
cell sheets, but also play critical roles in maintaining cell
polarity and signal transduction [3,5,6]. However, cancer
cells frequently exhibit abnormal TJ function [7].
Claudins are members of a large family of transmem-
brane proteins that are among the essential components
of TJs, and claudin-aberrant expression potentially leads
to structural and functional damage of TJs [8]. Presently, a
total of 24 claudin genes have been identified in mammals,
and they often show tissue-specific patterns of expression. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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aberrant expression of claudins in several human cancers
[10,11]. To our knowledge, the expression of Claudin-1, 2,
3, 4, 5, 6, 7, 18 and 23 have been reported in gastric can-
cers [12-23]. Among the various claudin proteins related
to gastric cancer, the function of claudin-4 was not con-
sistent. For example, Jung et al. [15] and Ohtani et al. [19]
found that the expression of claudin-4 significantly corre-
lated with favorable survival for patients with gastric
cancer in 72 and 124 cases, respectively. However, Resnick
et al. [13] reported that moderate to strong claudin-4
staining in gastric cancer was significantly associated with
poor survival in 146 cases. Soiniet al. [14] found no clear
association between claudin-4 expression and patient
prognosis in 118 cases. Interestingly also, the expression
of claudin-4 has been shown to play a role in determining
matrix metalloproteinase(MMP) activity, indicating that
claudin-4 might have mediated invasion through the acti-
vation of MMPs [24,25]. Furthermore, previous studies
reported that claudin-4 may have potential as a treatment
for cancer [26-28]. Thus, further investigations are re-
quired to clarify these controversial results and the real
functions of claudin-4. In this study, we aimed to identify
the clinicopathological associations and prognostic value
of claudin-4 expression in gastric cancer.
Methods
Patients and tissue samples
In this study, tissue specimens from a total of 329
patients with gastric cancer were obtained between 1998
and 2004 at the Department of Surgical Oncology, The
First Hospital of China Medical University. All patients
underwent curative radical gastrectomy with standard
lymph node dissection. The histopathological diagnosis
of 21 intestinal metaplasia, 21 dysplasia, 44 microscopic-
ally normal stomach mucosa, and 329 gastric adenocar-
cinoma samples from the 329 patients was performed by
two independent pathologists. We obtained written
informed consent from all patients, and the study was
approved by the ethics committee of the China Medical
University. None of the patients had received chemo-
therapy or radiotherapy before the surgical procedure.
The detailed postoperative pathology diagnosis reports
were obtained and included gender, age, tumor location,
size, differentiation status, growth pattern, and tumor-
node-metastasis (TNM) stage. The criteria of TNM clas-
sification for gastric carcinoma were in accordance with
the 7th 2010 American Joint Committee on Cancer
(AJCC) staging manual [29]. The criterion for histo-
pathological grading of differentiation was in accordance
with the 2000 world health organization classification of
gastric carcinoma [30]. The criterion for the pattern of
tumor growth was in accordance with the Japanese clas-
sification of gastric carcinoma, 3rd English edition. Allpatients’ characteristics are summarized in Table 1. The
patient sample comprised 238 male and 91 female
patients with a mean age of 57 years (range 26 to 81
years). All patients were followed up via telephone
inquiry or questionnaire, and the followup time ranged
from 1 to 136 months (median of 56 months).Immunohistochemistry
The formalin-fixed and paraffin-embedded (FFPE) tissue
blocks were sliced into 5-μm-thick sections, then depa-
raffinized with xylene and rehydrated using a graduated
series of ethanol. The sections were incubated in boiling
citric acid buffer (pH 6.0) for antigen retrieval in a steam
pressure cooker. The sections were incubated overnight at
4°C with the following primary antibodies: anti-claudin-4
monoclonal antibody, 1:100 dilution, clone 3E2C1, Zymed
Laboratories Inc., CA, USA. Immunohistochemical stain-
ing was conducted using the MaxVisionTMHRP-Polymer
anti-Mouse/Rabbit IHC Kit (Fuzhou Maixin, China) with
3 amino-9-ethyl carbazole (AEC) as the enzyme substrate.
The sections were then lightly counterstained with
hematoxylin. Positive controls were colonic mucosa and
the specimens in which the primary antibody was replaced
with non-reactive antibodies served as negative controls.
Immunostaining results were interpreted independ-
ently by two pathologists using a semi-quantitative scor-
ing system [31]. The immunostaining reactions were
evaluated by staining intensity (0, no stain; 1, weak; 2,
moderate; 3, strong) and the percentage of stained epi-
thelial cells (0, < 5%; 1, 5 to 25%; 2, 26 to 50%; 3, 51 to
75%; and 4, >75%). The percent positivity of epithelial
cells and staining intensity were then multiplied to
generate the immunoreactivity score (IS) for each case.
Specimens were rescored if there were discrepancies in
IS between the two pathologists, until a consensus was
reached. We divided the samples into two groups based
on the results of the immunostaining in the tissues: low
expression (IS < 4) and high expression (IS ≥ 4). This
evaluation system for claudin-4 has been used in previ-
ous studies [32].Statistical analysis
A meta-analysis was performed to confirm the role of
claudin-4 in gastric cancer. We searched the English
literature for relevant studies published before June 1st,
2013, using the PubMed database with the following
terms: ‘stomach neoplasm’ and ‘claudin-4’ in medical
subject headings (MeSH). References in the retrieved
articles were further screened for earlier original studies.
The inclusion criteria were patients with gastric cancer,
including a prognostic comparison between high and
low expression of claudin-4. The corresponding authors
were contacted to obtain missing information, and some









































IIIA, IIIB, IIIC 180
Vital statistics, number
Alive 152
Dead, all causes 177
Table 1 Clinicopathologic characteristics of 329 patients
with gastric carcinoma (Continued)
Dead, gastric cancer 143
Dead, unrelated 22
Information unavailable 12
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missing after repeated requests.
For the quantitative aggregation of survival results, the
observed-expected (O-E) statistic and variance were
combined to give the effective value. The O-E values
and the variances were estimated from available data
using the methods reported by Tierney et al. [33]. If the
study provided a hazard ratio (HR), the O-E values and
variances were estimated based on that. If the study did
not provide a HR but reported the data in the form of a
survival curve, survival rates were extracted at certain
specified times to reconstruct an estimated HR and its
variance.
We used the chi-squared test to evaluate the relation-
ship between claudin-4 expression and various clinico-
pathological parameters. Survival analysis was performed
using the Kaplan-Meier method, and differences be-
tween the groups were analyzed using the log-rank test.
The Cox regression multivariate model was used in a
stepwise forward manner to detect the independent pre-
dictors of survival. Two-tailed P-values less than 0.05
were considered to indicate a statistically significant
result. All statistical analyses were performed using SPSS
software (version 17.0; SPSS for Windows, Chicago, IL,
USA) and RevMan 5.2 analysis software (The Cochrane
Collaboration).
Results
Claudin-4 immunostaining occurred in a predominantly
membranous pattern, with some samples displaying a
low level of cytoplasmic staining. Only 15.9% (7/44) of
normal gastric mucosa exhibited high expression levels
of claudin-4. In contrast, 90.5% (19/21) of the intestinal
metaplasia lesions and 95.2% (20/21) of the gastric epi-
thelial dysplasia lesions exhibited high expression levels
of claudin-4. Of the gastric carcinoma samples investi-
gated, 53.2% (175/329) of cases demonstrated high
claudin-4 expression (Figure 1).
The expression level of claudin-4 was significantly corre-
lated with tumor differentiation (P < 0.001), gender (P =
0.003), age (P = 0.025) and tumor location (P = 0.033).
According to microscopic inspection of the tumor growth
pattern, 76 cases were classified as the expanding type and
172 cases as the infiltrative type, whereas 81 cases were
determined to be the intermediate type. The expression
level of claudin-4 was also significantly correlated with the
tumor growth pattern (P < 0.001). High expression of
Figure 1 Claudin-4 immunostaining. (A) Normal gastric muscoma, no staining; (B) intestinal metaplasia, high expression; (C) moderately
differentiated to well-differentiated gastric cancer, high expression; (D) poorly differentiated gastric cancer, no staining. Magnification × 200.
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and 72.8% of the intermediate type of gastric cancer,
whereas only 36.6% of the infiltrative type exhibited high
expression. However, our findings revealed no significant
correlation between the expression of claudin-4 and
tumor size, depth of invasion, lymph node metastasis,
lymphatic invasion, and tumor stage (Figure 2, Table 2).
In total 19 studies were initially identified. Fourteen
studies were excluded because they did not include aFigure 2 Expression of claudin-4 in normal stomach mucosa, intestina
intermediate and infiltrative types).prognostic comparison between high and low expression
of claudin-4. One further study was excluded because
critical information was missing [14]. Only one study
performed the prognostic comparison based on cause-
specific survival (CSS) [13], so it was excluded and we
made overall survival (OS) the primary end point of our
meta-analysis. Three studies met the inclusion criteria
and were included in the final analysis [15,19,34]. Pooled
analysis indicated that the OS of patients with highl metaplasia, dysplasia and cancer (including expanding,
Table 2 Statistical results of relationships between















Age at surgery,y 0.025
≤ 60 192 100(52.1) 92(47.9)
> 60 137 54(39.4) 83(60.6)
Gender 0.003
Male 238 99(41.6) 139(58.4)
Female 91 55(60.4) 36(39.6)
Pathophysiologic
features
Tumor size (cm) 0.055
≤ 5 199 102(51.3) 97(48.7)
>5 130 52(40.0) 78(60.0)
Tumor location 0.033
Upper 31 9(29.0) 22(71.0)
Middle 53 31(58.5) 22(41.5)









Expanding 76 23(30.3) 53(69.7)
Intermediate 81 22(27.2) 59(72.8)
Infiltrative 172 109(63.4) 63(36.6)
T stage 0.147
T1/2 96 51(53.1) 45(46.9)




Negative 101 48(47.5) 53(52.5)
Positive 228 106(46.5) 122(53.5)
Lymphatic invasion 0.898
Negative 248 117(47.2) 131(52.8)
Positive 81 37(45.7) 44(54.3)
Tumor stage 0.589
IA, IB 63 33(52.4) 30(47.6)
IIA, IIB 86 38(44.2) 48(55.8)
IIIA, IIIB, IIIC 180 83(46.1) 97(53.9)
WD, well-differentiated; MD, moderately differentiated; PD, poorly
differentiated, UD, undifferentiated.
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4 (Figure 3).
According to univariate survival analysis, claudin protein
expression was not associated with patients’ CSS (P =
0.637) or OS (P = 0.469). Stratified subclass survival ana-
lyses were performed for T and N status, lymphatic inva-
sion, and tumor stage, and no prognostic difference was
found (Additional file 1: Figure S1). In the comparison of
CSS, only TNM stage (P < 0.001) and lymphatic invasion
(P < 0.001) were significant prognostic factors. After Cox
multivariate analysis, only TNM stage was a significant
prognostic factor (P < 0.001). No survival difference was
observed between the three types of tumor growth pattern
(P = 0.069, Figure 4A). Further stratified analysis de-
monstrated no significant prognostic difference between
patients who exhibited high versus low expression of
claudin-4 in expanding and infiltrative type gastric cancer.
However, in intermediate type growth pattern gastric can-
cer, the prognosis for patients exhibiting low expression
levels of claudin-4 was significantly better compared to
those with high expression levels (P = 0.023, Figure 4B).
This result was also confirmed by the Cox multivariate
analysis (P = 0.037). The five-year cancer-specific survival
rate for patients with low claudin-4 expression levels in
intermediate-type gastric cancer was 76.4%, which was
similar to all expanding-type gastric cancers (64.5%). Our
findings indicated that the five-year CSS rate for patients
exhibiting high expression levels of claudin-4 in inter-
mediate-type gastric cancer was 46.6%, which was similar
to infiltrative-type gastric cancers (50.7%) (Figure 4C).
Through the staining of claudin-4 in the intermediate
type, we reclassified the low expression of claudin-4 into
expanding type and high expression of claudin-4 into infil-
trative type and composed two novel subgroups. There
was a significant difference in prognosis between these
two novel subgroups(P = 0.003, Figure 4D). After subclass
survival analysis stratified by T status, N status, lymphatic
invasion and tumor stage, we found that the prognostic
differences of two novel subgroups were significant in the
pT3/4, LN(+), stage III, lymph invasion(−) (Additional file
2: Figure S2). In multivariate analysis, the novel classifica-
tion was a significant prognostic factor (P = 0.007).Discussion
The claudin family of proteins plays an important role in
the maintenance of TJ function, and the expression
levels often exhibit a tissue-specific pattern. Recently, an
accumulating number of studies have demonstrated ec-
topic or aberrant expression of claudins in many tumor
types [25,32,35-37]. Among the claudin subtypes, the
expression of claudin-4 is frequently altered in various
tumor tissues. Claudin-4 is an integral membrane pro-
tein that belongs to the claudin family. This protein is a
Figure 3 Forest plot of the association between overall survival and the expression of claudin-4. O-E, observed-expected.
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sheets and controlling paracellular ion flux [10].
Relatively few studies have examined the expression
levels of claudin-4 in precursor lesions. Cunningham et al.
[38] reported a 15% expression level of claudin-4 in the
normal stomach, whereas in both intestinal metaplasia
and dysplasia the expression of claudin-4 reached 100%.
Matsuda et al. [36] also reported that claudin-4 was
detected in the epithelium of intestinal metaplasia but not
in normal epithelium. Our staining results of precursor
lesion samples were in concordance with these studies.
The high expression rate of claudin-4 in normal gastric
mucosa was very low (only 15.9%), whereas intestinal
metaplasia lesions and gastric epithelial dysplasia lesions
exhibited a high expression level close to 100%. Because
CLDN-4 is expressed at high levels in the normal small
intestine and colon [11], its increased expression in intes-
tinal metaplasia is easily comprehended. However, the
differential expression of claudin-4 in normal mucosa and
cells exhibiting dysplasia remains unclear. The primary
morphological features of epithelial dysplasia are cellular
atypia, abnormal differentiation, and disorganized mucosal
architecture; these changes are potentially associated with
elevated claudin-4 expression. The specific underlying me-
chanisms need to be further elucidated. Taken together,
our findings indicate that claudin-4 could potentially serve
as a molecular marker of intestinal metaplasia and dyspla-
sia in gastric mucosa.Figure 4 Kaplan-Meier survival curves. (A) Comparison of survival for thre
low and high expression levels of claudin-4 in intermediate-type growth pattern
expression levels of claudin-4 in intermediate-type, high expression levels of cla
Comparison of survival in two novel subgroups.In the present study, we found that decreased expression
of claudin-4 was significantly associated with histological
differentiation in gastric cancer. The differentiated group
exhibited a higher expression rate of claudin-4 compared
to the undifferentiated group. Lee et al. [18] reported that
reduced expression of claudin-4 correlated with disruption
of glandular structure and loss of differentiation, which
was in concordance with our results.
The role of claudin-4 for prognosis remains controver-
sial. Resnicket al. [13] reported that increased claudin-4
expression was a poor prognostic factor for CSS in 146
patients, and Soini et al. [14] proposed that claudin-4
did not associate with OS. However, the results of the
meta-analysis of this study suggest that OS of patients
with high claudin-4 was better than that of patients with
low claudin-4. The results survival analysis based on
patients in our institution indicated that claudin-4 was
not associated with CSS or OS, which was similar to the
results of Soini et al., but different from other studies.
Some previous studies have suggested that upregulation
of certain claudins potentially contributes to neoplasia by
directly altering TJ function [39]. Overexpression of
claudin-3 and 4 may lead to an increase in invasion, motil-
ity and tumor cell survival [25]. On the contrary, in pan-
creatic carcinoma, overexpression of claudin-4 has been
associated with significantly reduced invasiveness both
in vitro and in vivo [40]. Although our study comprises
nearly the largest number of cases at present, the prognostice types of tumor growth pattern; (B) comparison of survival in patients with
gastric cancer; (C) Kaplan-Meier survival curves for expanding-type, low
udin-4 in intermediate-type, and infiltrative-type gastric cancers. (D)
Figure 5 Hematoxylin-eosin staining. The three different growth
patterns of gastric cancer: (A) expanding type; (B) intermediate type;
(C) infiltrative type. Magnification × 100.
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0.637). It is possible that different populations and different
environments contribute to these different results. Further
study including a greater number of samples is warranted.
Histological growth patterns are important parameters
for assessment of the biological behavior of gastric can-
cer. Based on patterns of growth and invasiveness, Ming
[41] reported two types of gastric cancer, the expanding
and the infiltrative type.The Japanese Gastric Cancer
Association divided gastric cancer into three types based
on tumor-infiltrating (INF) growth into surrounding
tissue: in INFa, the tumor displays expanding growth
with a distinct border from the surrounding tissue; in
INFb, the tumor shows an intermediate pattern between
INFa and INFc; in INFc, the tumor displays infiltrative
growth with no distinct border with the surrounding tissue
[42]. This final type is closer to our clinical practice, in
which the intermediate type exists and is difficult to classify
(Figure 5). In our results, there were differences in survival
between the three types, but not significant (P = 0.069).
Survival rates in patients with the intermediate type were
between the expanding and the infiltrative types. Interest-
ingly, in stratified analysis we found that high claudin-4
expression was associated with poor prognosis in the inter-
mediate growth pattern (P = 0.023). The five-year survival
rate with low expression of claudin-4 in the intermediate
type (76.4%) was similar to the expanding type (64.5%),
while the group with high expression of claudin-4(46.6%)
was closer to the infiltrative type (50.7%). Thus, we could
potentially classify intermediate-type patients according
to the staining of claudin-4. We reclassified patients with
low expression of claudin-4 in the intermediate group as
having the expanding type, and patients with high
expression of claudin-4 as having the infiltrative type of
tumor. Both the univariate and multivariate analyses con-
firmed that there were significant differences in survival
between these two subgroups. After stratified subclasses
survival analysis, we found that the prognostic differ-
ences in the two novel subgroups were significant in the
pT3/4, LN(+), stage III, lymph invasion(−). Although no
significant difference was found in other subclasses, a
certain trend still existed and we considered that the
negative results of the statistical analysis were because of
the relatively small sample size. Thus, the expression of
claudin-4 could potentially be utilized as a basis to fur-
ther identify gastric cancers of the intermediate type.
The biological role of claudin-4 in gastric cancer re-
mains unclear. It has been previously reported that
CLDN18 is specifically expressed in normal gastric mu-
cosa, but not CLDN4 [11,22]. Claudin-4 is upregulated
in gastric adenocarcinomas, and increased claudin-4 ex-
pression is more commonly seen in intestinal-type as
opposed to diffuse-type tumors [13,17]. However, claudin-
18 is downregulated in intestinal-type gastric cancer [22].These results suggest that the distribution and expression
levels of claudin proteins may vary in different cells and
tissues of the body [43]. Ectopic expression of claudin is
potentially associated with tumor progression. Further
studies are warranted to elucidate the function of claudin-
4 in the progression of gastric cancer.
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We demonstrated upregulation of claudin-4 in intestinal
metaplasia and gastric epithelial dysplasia, which suggests
its potential utility as a biomarker in gastric adenocarcin-
oma precursor lesions. Expression of claudin-4 was not
associated with survival, but it was associated with poor
histological differentiation and infiltrative patterns of
tumor growth. Moreover, this study demonstrated that
expression of claudin-4 could potentially be utilized as a
basis to further identify gastric cancers of the intermediate
type.
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